163 related articles for article (PubMed ID: 32379447)
21. MMpI: A WideRange of Available Compounds of Matrix Metalloproteinase Inhibitors.
Muvva C; Patra S; Venkatesan S
PLoS One; 2016; 11(8):e0159321. PubMed ID: 27509041
[TBL] [Abstract][Full Text] [Related]
22. Biphenyl substituted lysine derivatives as recognition elements for the matrix metalloproteinases MMP-2 and MMP-9.
Kirchhain A; Zubrienė A; Kairys V; Vivaldi F; Bonini A; Biagini D; Santalucia D; Matulis D; Di Francesco F
Bioorg Chem; 2021 Oct; 115():105155. PubMed ID: 34303036
[TBL] [Abstract][Full Text] [Related]
23. Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke RE; Libert C
Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
[TBL] [Abstract][Full Text] [Related]
24. Drug Design Inspired by Nature: Crystallographic Detection of an Auto-Tailored Protease Inhibitor Template.
Gall FM; Hohl D; Frasson D; Wermelinger T; Mittl PRE; Sievers M; Riedl R
Angew Chem Int Ed Engl; 2019 Mar; 58(12):4051-4055. PubMed ID: 30615822
[TBL] [Abstract][Full Text] [Related]
25. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
[TBL] [Abstract][Full Text] [Related]
26. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
Fabre B; Ramos A; de Pascual-Teresa B
J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
[TBL] [Abstract][Full Text] [Related]
27. A comparative docking study and the design of potentially selective MMP inhibitors.
Hanessian S; Moitessier N; Therrien E
J Comput Aided Mol Des; 2001 Oct; 15(10):873-81. PubMed ID: 11918074
[TBL] [Abstract][Full Text] [Related]
28. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
29. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
30. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
[TBL] [Abstract][Full Text] [Related]
31. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.
Foley LH; Palermo R; Dunten P; Wang P
Bioorg Med Chem Lett; 2001 Apr; 11(8):969-72. PubMed ID: 11327602
[TBL] [Abstract][Full Text] [Related]
32. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations.
Ara A; Kadoya R; Ishimura H; Shimamura K; Sylte I; Kurita N
J Mol Graph Model; 2017 Aug; 75():277-286. PubMed ID: 28618335
[TBL] [Abstract][Full Text] [Related]
33. Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.
Beutel B; Daniliuc CG; Riemann B; Schäfers M; Haufe G
Bioorg Med Chem; 2016 Feb; 24(4):902-9. PubMed ID: 26810711
[TBL] [Abstract][Full Text] [Related]
34. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
35. Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation.
Huang RZ; Liang GB; Huang XC; Zhang B; Zhou MM; Liao ZX; Wang HS
Eur J Med Chem; 2017 Sep; 138():979-992. PubMed ID: 28756264
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
Fields GB
Front Immunol; 2019; 10():1278. PubMed ID: 31214203
[TBL] [Abstract][Full Text] [Related]
37. Similarity of binding sites of human matrix metalloproteinases.
Lukacova V; Zhang Y; Mackov M; Baricic P; Raha S; Calvo JA; Balaz S
J Biol Chem; 2004 Apr; 279(14):14194-200. PubMed ID: 14732707
[TBL] [Abstract][Full Text] [Related]
38. Enzymatic inhibitory activity of iridoid glycosides from Picrorrhiza kurroa against matrix metalloproteinases: Correlating in vitro targeted screening and docking.
Rathee D; Lather V; Grewal AS; Dureja H
Comput Biol Chem; 2019 Feb; 78():28-36. PubMed ID: 30497018
[TBL] [Abstract][Full Text] [Related]
39. In vitro biological evaluation of glyburide as potential inhibitor of collagenases.
Bodiga VL; Eda SR; Chavali S; Revur NN; Zhang A; Thokala S; Bodiga S
Int J Biol Macromol; 2014 Sep; 70():187-92. PubMed ID: 25008133
[TBL] [Abstract][Full Text] [Related]
40. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
